FR-α is a glycosylphosphatidylinositol-anchored receptor that is overexpressed in various cancer types, including ovarian, breast, and lung cancers, providing a selective target for FA-modified cancer therapies 23-25. This evidence concerns the gene FOLR1 and cancer.